Stock prices for Zealand Pharma plummeted over 20% during Monday morning trading following the release of clinical trial results that revealed concerning issues with the company’s weight-loss medication survodutide.
The trial data indicated that patients taking the obesity treatment experienced more severe adverse reactions and were more likely to discontinue participation in the study when compared to competing medications in the same therapeutic category.
The Danish pharmaceutical company’s significant stock decline occurred in Copenhagen markets as investors reacted to the disappointing clinical findings on June 8th.
